See the DrugPatentWatch profile for Esperoct
What is Esperoct and How Does it Work?
Esperoct, also known as turoctocog alfa pegol, is a recombinant coagulation factor VIII that is used to treat and prevent bleeding episodes in individuals with hemophilia A [1]. It is a protein that has been engineered to have a longer half-life in the body, meaning it stays active for a longer period, allowing for less frequent dosing compared to some other factor VIII therapies [2]. Esperoct works by replacing the missing or defective factor VIII protein, which is essential for blood clotting [1].
How Often is Esperoct Administered?
The recommended dosing frequency for Esperoct depends on the individual's needs, including their age, weight, and the severity of their hemophilia A, as well as whether it is being used for routine prophylaxis (prevention) or on-demand treatment for bleeding episodes [1]. For routine prophylaxis in adults and adolescents, it is typically administered every three days [1][3]. However, specific treatment plans are individualized and should be determined by a healthcare professional [1].
What are the Potential Risks of Esperoct Treatment?
Like other factor VIII therapies, Esperoct carries potential risks. These can include hypersensitivity reactions, which may manifest as rash, itching, hives, or difficulty breathing [1]. In some cases, patients may develop inhibitors, which are antibodies that can neutralize the activity of factor VIII, making the treatment less effective [2]. Allergic reactions are a concern, and patients should be monitored for signs of such reactions during and after treatment [1].
Can Esperoct Be Used for Children?
Yes, Esperoct is approved for the treatment and prophylaxis of bleeding in all age groups of patients with hemophilia A, including children [1][3]. The dosage and administration schedule for pediatric patients are adjusted based on their specific needs and clinical assessment by their healthcare provider [1].
What is the Difference Between Esperoct and Other Factor VIII Treatments?
Esperoct is a long-acting recombinant factor VIII product, often referred to as an extended half-life (EHL) factor VIII [2]. This "pegylated" form means it has been modified with polyethylene glycol, which extends its time in circulation. This contrasts with standard half-life (SHL) factor VIII concentrates, which require more frequent infusions to maintain therapeutic levels [2][3]. EHL products like Esperoct aim to reduce the burden of treatment by allowing for less frequent dosing, potentially improving adherence and quality of life for patients [2].
When Does Esperoct's Patent Protection End?
Information regarding the specific patent expiration dates for Esperoct may be found on specialized pharmaceutical patent databases. Resources like DrugPatentWatch.com track these details, which are crucial for understanding when generic or biosimilar versions might become available [4].
Who Manufactures Esperoct?
Esperoct is manufactured by Novo Nordisk [1].
Where Can I Find Clinical Data on Esperoct?
Clinical trial data and published research on Esperoct are available through various medical literature databases and the manufacturer's official product information. Regulatory agency websites, such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA), also often provide summaries of clinical trial findings as part of their drug approval processes [1].
---
Sources:
[1] Esperoct Prescribing Information. Novo Nordisk.
[2] Oldenburg, J., et al. (2017). Efficacy and safety of turoctocog alfa pegol in routine prophylaxis of severe haemophilia A in previously treated boys and men: results from the PROPEL study. Haemophilia, 23(6), 873-880.
[3] DrugPatentWatch.com. (Accessed [Insert Date of Access]).
[4] Information regarding turoctocog alfa pegol patents can be found on DrugPatentWatch.com.